H E L L E N I C   J O U R N A L  OF   N U C L E A R   M E D I C I N E

The Journal of the Hellenic Society of Nuclear Medicine

____________________________

Hell J Nucl Med 1999, 3: 155-159

 

Familial Medullary Thyroid Carcinoma: Report of Five Cases in Two Families

D. Piciu1, A. Porutiu1, D. Eniu2, A. Rasinariu1

1. Oncological Institute "Prof. I. Chiricuta", Cluj-Napoca

2. University of Medicine, Cluj-Napoca, Romania

 

Summary

Five cases of medullary thyroid carcinoma (MTC) in 2 families, which were diagnosed at the Oncological Institute in 1998, were studied in order to correlate clinical, histological and immunological findings. All patients were female, with a mean age of 25.2 years, 2 patients being adults and 3 children. One patient had hyperparathyroidism associated with familial MTC, and the other 4 had familial MTC without any evidence of other endocrinopathies. The mean follow-up time was 28,2 months (37 months in Case 1, 11 months in Case 2, 10 months in Case 3, 77 months in Case 4 and 10 months in Case 5).

In 3 cases the diagnosis was suspected only because of the family history and the values of serum CEA (carcinoembryonic antigen), since the patients had no clinical signs. In the other 2 cases, family history and serum CEA levels were accompanied by the presence of 1 cervical nodule. In all cases serum calcitonin (Ct) levels had not been pre- or post-operatively measured. This did not delay the final diagnosis, which was based on the pathology of the operated gland. Final diagnosis was made within 3 weeks, after the patients were admitted to our institute. All patients underwent total thyroidectomy and occasional ablative radioiodine therapy with or without cobalt radiotherapy.

This presentation is interesting not only because the familial form of MTC is rare, but also because of the favourable outcome of the disease after a combined form of treatment was applied.

Key words

- medullary thyroid carcinoma

- familial form

- CEA ( carcinoembryonic antigen )

- radiotherapy

Correspondence address: Dr. Piciu Doina MD, PhD, Department of Nuclear Medicine, Oncological Institute 34-36, Republicii 3400, Cluj-Napoca, Romania